Table 2.
Comparison of baseline characteristics between the unmatched and 2:1 matched LDP and RDP patients
| LDP | RDP | ESb | p | LDP | RDP | ESb | p | |
|---|---|---|---|---|---|---|---|---|
| N | 1144 | 393 | 698 | 349 | ||||
| Year of procedure | 0.217 | < 0.001a | 0.002 | 0.181 | ||||
| 2010 | 63 (5.5%) | 6 (1.5%) | 14 (2.0%) | 5 (1.4%) | ||||
| 2011 | 68 (5.9%) | 10 (2.5%) | 11 (1.6%) | 10 (2.9%) | ||||
| 2012 | 88 (7.7%) | 7 (1.8%) | 31 (4.4%) | 7 (2.0%) | ||||
| 2013 | 101 (8.8%) | 32 (8.1%) | 44 (6.3%) | 32 (9.2%) | ||||
| 2014 | 102 (8.9%) | 24 (6.1%) | 45 (6.4%) | 24 (6.9%) | ||||
| 2015 | 94 (8.2%) | 26 (6.6%) | 55 (7.9%) | 26 (7.4%) | ||||
| 2016 | 134 (11.7%) | 37 (9.4%) | 94 (13.5%) | 37 (10.6%) | ||||
| 2017 | 119 (10.4%) | 50 (12.7%) | 94 (13.5%) | 49 (14.0%) | ||||
| 2018 | 137 (12.0%) | 58 (14.8%) | 118 (16.9%) | 52 (14.9%) | ||||
| 2019 | 115 (10.1%) | 85 (21.6%) | 99 (14.2%) | 64 (18.3%) | ||||
| 2020 | 123 (10.8%) | 58 (14.8%) | 93 (13.3%) | 43 (12.3%) | ||||
| Age | 67.8 ± 11.2 | 68.7 ± 10.3 | 0.076 | 0.193 | 68.6 ± 10.5 | 68.7 ± 10.2 | 0.013 | 0.848 |
| Sex | 0.017 | 0.498 | 0.031 | 0.861 | ||||
| Male | 545 (47.6%) | 195 (49.6%) | 344 (49.3%) | 170 (48.7%) | ||||
| Female | 599 (52.4%) | 198 (50.4%) | 354 (50.7%) | 179 (51.3%) | ||||
| Race | 0.025 | 0.503 | 0.002 | 0.438 | ||||
| White | 916 (80.1%) | 304 (77.4%) | 556 (79.7%) | 274 (78.5%) | ||||
| Black | 130 (11.4%) | 52 (13.2%) | 73 (10.5%) | 45 (12.9%) | ||||
| Other | 98 (8.6%) | 37 (9.4%) | 69 (9.9%) | 30 (8.6%) | ||||
| Charlson score | 0.024 | 0.728 | 0.010 | 0.828 | ||||
| 0 | 651 (56.9%) | 232 (59.0%) | 408 (58.5%) | 198 (56.7%) | ||||
| 1 | 322 (28.1%) | 107 (27.2%) | 190 (27.2%) | 98 (28.1%) | ||||
| 2 | 90 (7.9%) | 32 (8.1%) | 52 (7.4%) | 31 (8.9%) | ||||
| 3 | 81 (7.1%) | 22 (5.6%) | 48 (6.9%) | 22 (6.3%) | ||||
| T stage | 0.166 | 0.004a | 0.028 | 0.496 | ||||
| T1 | 236 (20.6%) | 83 (21.1%) | 158 (22.6%) | 72 (20.6%) | ||||
| T2 | 275 (24.0%) | 126 (32.1%) | 187 (26.8%) | 105 (30.1%) | ||||
| T3 | 633 (55.3%) | 184 (46.8%) | 353 (50.6%) | 172 (49.3%) | ||||
| Neoadjuvant therapy | ||||||||
| Chemotherapy | 198 (17.3%) | 100 (25.4%) | 0.090 | < 0.001a | 131 (18.8%) | 73 (20.9%) | 0.024 | 0.410 |
| Radiation | 59 (5.2%) | 17 (4.3%) | 0.019 | 0.512 | 33 (4.7%) | 16 (4.6%) | 0.001 | 0.917 |
ES Effect Size, LDP Laparoscopic Distal Pancreatectomy, RDP Robotic Distal Pancreatectomy, SD Standard Difference
aStatistically significant
bEffect Size is calculated as Theil’s U value for categorical variables and Cohen’s d standard difference for continuous variables